Tatva Chintan Pharma Intrinsic Value
Tatva Chintan Pharma intrinsic value. Tatva Chintan Pharma (TATVA) median intrinsic value is ₹539.70 from 10 valuation models (range ₹360–₹900), vs current price ₹1799.00 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with TATVA stock valuation models to assess whether the stock is under or overvalued.
TATVA Valuation Methods Summary — DCF, Graham Number & P/E
Tatva Chintan Pharma intrinsic value across 10 models vs current price ₹1799.00 — upside/downside and value range per method. For current market price and key ratios, visit Tatva Chintan Pharma screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹539.70 | ₹431.76 - ₹647.64 | -70.0% | EPS: ₹17.64, Sector P/E: 12x |
| Book Value Method | asset | ₹359.80 | ₹323.82 - ₹395.78 | -80.0% | Book Value/Share: ₹340.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹539.70 | ₹485.73 - ₹593.67 | -70.0% | Revenue/Share: ₹233.04, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹719.60 | ₹647.64 - ₹791.56 | -60.0% | EBITDA: ₹112.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹719.60 | ₹575.68 - ₹863.52 | -60.0% | CF Growth: 12.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹539.70 | ₹485.73 - ₹593.67 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹539.70 | ₹485.73 - ₹593.67 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹899.50 | ₹809.55 - ₹989.45 | -50.0% | ROE: 5.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹539.70 | ₹485.73 - ₹593.67 | -70.0% | EPS: ₹17.64, BVPS: ₹340.00 |
| Dividend Yield Method | dividend | ₹539.70 | ₹485.73 - ₹593.67 | -70.0% | DPS: ₹2.00, Target Yield: 3.5% |
TATVA Intrinsic Value vs Market Price — All Valuation Models
Tatva Chintan Pharma fair value range ₹360–₹900 vs current market price ₹1799.00 across 10 valuation models. Read Tatva Chintan Pharma dividend policy for the complete payout history and dividend yield track record.
TATVA Intrinsic Value Analysis — Undervalued or Overvalued?
Tatva Chintan Pharma median intrinsic value ₹539.70, current price ₹1799.00 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of TATVA?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Tatva Chintan Pharma (TATVA) is ₹539.70 (median value). With the current market price of ₹1799.00, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹359.80 to ₹899.50, indicating ₹359.80 - ₹899.50.
Is TATVA undervalued or overvalued?
Based on our multi-method analysis, Tatva Chintan Pharma (TATVA) appears to be trading above calculated value by approximately 70.0%.
TATVA Financial Health — Key Ratios vs Industry Benchmarks
Tatva Chintan Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 38.89 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.53x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
TATVA Cash Flow Quality — Operating & Free Cash Flow
Tatva Chintan Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹32 Cr | ₹-26 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹25 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹98 Cr | ₹38 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹28 Cr | ₹-23 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹20 Cr | ₹-79 Cr | Positive Operating Cash Flow | 6/10 |